R. Weaver

发表

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

M. Piccart, L. Carey, A. Bardia, 2021, The New England journal of medicine.

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

C. White, C. Varns, J. Leonard, 2000, Current pharmaceutical biotechnology.

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.

M. Czuczman, Judy R. Berlfein, A. Grillo‐López, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

M. Czuczman, P. McLaughlin, A. Grillo‐López, 2006, Leukemia & lymphoma.

Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.

Antonio J. Grillo-López, P. Multani, C. White, 2001, Current pharmaceutical biotechnology.

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

M. Czuczman, D. Maloney, J. Rosenberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

A. Stopeck, A. Forero, D. Yardley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody-targeted immunotherapy for treatment of malignancy.

C. White, A. Grillo‐López, R. Weaver, 2001, Annual review of medicine.

Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

M. Czuczman, D. Maloney, P. Mclaughlin, 2000 .

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

D. Maloney, W. Velasquez, R. Dillman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study

A. Stopeck, A. Forero, D. Citron, 2012 .

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

M. Piccart, L. Carey, A. Bardia, 2021, New England Journal of Medicine.